Rep. Byron Donalds Sells Abbott Laboratories (NYSE:ABT) Stock

Representative Byron Donalds (R-Florida) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on January 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on December 4th. The trade occurred in the Representative’s “MORAN WEALTH IRA” account.

Representative Byron Donalds also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Comfort Systems USA (NYSE:FIX) on 12/4/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 10/24/2025.
• Purchased $1,001 – $15,000 in shares of Brown & Brown (NYSE:BRO) on 10/24/2025.
• Purchased $1,001 – $15,000 in shares of Progressive (NYSE:PGR) on 10/24/2025.
• Sold $1,001 – $15,000 in shares of Howmet Aerospace (NYSE:HWM) on 10/23/2025.
• Purchased $1,001 – $15,000 in shares of Trade Desk (NASDAQ:TTD) on 10/9/2025.
• Purchased $1,001 – $15,000 in shares of Progressive (NYSE:PGR) on 10/9/2025.
• Purchased $1,001 – $15,000 in shares of Chipotle Mexican Grill (NYSE:CMG) on 10/9/2025.
• Purchased $1,001 – $15,000 in shares of Carnival (NYSE:CCL) on 10/9/2025.
• Purchased $1,001 – $15,000 in shares of Fortinet (NASDAQ:FTNT) on 10/9/2025.

Abbott Laboratories Trading Down 0.7%

NYSE ABT opened at $126.21 on Friday. The stock has a market cap of $219.46 billion, a P/E ratio of 15.82, a price-to-earnings-growth ratio of 2.10 and a beta of 0.72. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The stock has a 50 day simple moving average of $126.08 and a two-hundred day simple moving average of $129.47. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 EPS for the quarter, meeting analysts’ consensus estimates of $1.30. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The company had revenue of $11.37 billion during the quarter, compared to the consensus estimate of $11.40 billion. During the same quarter in the prior year, the company earned $1.21 earnings per share. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio is currently 29.57%.

Institutional Investors Weigh In On Abbott Laboratories

Several institutional investors have recently modified their holdings of ABT. IMG Wealth Management Inc. lifted its position in Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after purchasing an additional 167 shares in the last quarter. Cloud Capital Management LLC purchased a new position in shares of Abbott Laboratories during the 3rd quarter valued at about $29,000. Guerra Advisors Inc bought a new position in shares of Abbott Laboratories during the 3rd quarter valued at approximately $31,000. Anfield Capital Management LLC increased its holdings in Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after acquiring an additional 104 shares in the last quarter. Finally, Delos Wealth Advisors LLC bought a new stake in Abbott Laboratories during the 2nd quarter worth approximately $32,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ABT has been the topic of several research analyst reports. The Goldman Sachs Group boosted their price target on shares of Abbott Laboratories from $153.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. Raymond James Financial upped their target price on Abbott Laboratories from $141.00 to $146.00 and gave the stock an “outperform” rating in a report on Thursday, October 16th. Evercore ISI raised their target price on Abbott Laboratories from $142.00 to $144.00 and gave the company an “outperform” rating in a research note on Monday. Royal Bank Of Canada restated an “outperform” rating and set a $147.00 price target on shares of Abbott Laboratories in a research report on Thursday, October 16th. Finally, BTIG Research reiterated a “buy” rating and issued a $145.00 price objective on shares of Abbott Laboratories in a report on Thursday, November 20th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $147.47.

About Representative Donalds

Byron Donalds (Republican Party) is a member of the U.S. House, representing Florida’s 19th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027.

Donalds (Republican Party) is running for re-election to the U.S. House to represent Florida’s 19th Congressional District. He declared candidacy for the 2026 election.

Byron Donalds was born in Brooklyn, New York, and lives in Naples, Florida. Donalds earned a bachelor’s degree in finance and marketing from Florida State University in 2002. His career experience includes working as a commercial credit officer in banking and as a portfolio manager in financial services.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.